RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.

Derek DustinGuowei GuAmanda R BeyerSarah K HerzogDavid G EdwardsHangqing LinThomas L GonzalezSandra L GrimmCristian CoarfaDoug W ChanBeom-Jun KimJean-Paul De La OMatthew J EllisDan LiuShunqiang LiAlana L Welm Suzanne A W Fuqua

Published in: British journal of cancer (2020)

Our results demonstrate that RON/PI3K pathway inhibition may be an effective treatment strategy in ESR1 mutant and PalbR MBC patients. Clinically our data predict that ET resistance mechanisms can also contribute to CDK4/6 inhibitor resistance.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
estrogen receptor
peritoneal dialysis
prognostic factors
machine learning
big data
combination therapy